Ontiveros GAG, Gutiérrez VG, Lazo GMR

Language: Spanish
References: 28
Page: 177-183
PDF size: 197.29 Kb.

ABSTRACT

Bacterial toxins such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA) can be found in Gram-negative and Gram-positive bacteria, respectively. This toxins cause an inflammatory process denominated pulpitis. In the present study, the effect of LTA and LPS on the expression of cyclooxygenase-2 in human dental pulp cells was investigated. For this study a hypothesis was made, that this molecules take part in the dental pulp inflammatory process through the cyclooxygenase-2 synthesis in human pulp cells. To evaluate this hypothesis the effect of LPS and LTA was studied in primary cultures of human pulp cells. Finally, the pathways and molecules involved in COX-2 expression were characterized. In human dental pulp cells treated with LTA or LPS, it was detected that these molecules promote COX-2 expression. On the other hand, it was founded that the expression of COX-2 in human pulp cells was blocked by treatments with SB203580, PD98059, and Estaurosporine. The results of the present study demonstrate that treatments with LTA and LPS promote COX-2 expression in events related with protein kinase p38, ERK and PKC. The findings of this investigation are important because COX-2 is related to the synthesis of PGE2, which leads to a chronic inflammatory process. Finally, the nature of a mediator implied in the pulpitis process was characterized.

REFERENCES

1. Cohen S, Burns R. Vías de la pulpa. Editorial Elsevier Science. Octava edición. Madrid España. 2002: 405-595.

2. Weine F. Tratamiento endodóntico. Quinta edición. Madrid España. Editorial Harcourt. 2000: 79-134.

3. Love RM, Jenkinson HF. Invasion of dentinal tubules by oral bacteria. Crit Rev Oral Biol Med 2002; 13(2): 171-183.

4. Gutiérrez G, Kawasaki P. Los lipopolisacáridos: Estructura, receptores y transducción de señales. Simposium de Transducción de Señales. Universidad Nacional Autónoma de México. Julio 2002: 31-38.

5. Yang L, Tsai C. Induction of vascular endothelial growth factor expression in human pulp fibroblasts stimulated with black-pigmented Bacteroides. Int Endod Journal 2004; 37: 588-592.

6. Gruber R, Kandler B. Dental pulp fibroblasts contain target cells for lysophosphatidic acid. J Dent Res 2004; 83: 491-495.

7. Telles P, Hanks C. Lipoteichoic acid Up-regulates VEGF expression in macrophages and pulp cells. J Dent Res 2003; 82: 466-470.

8. Tokuda M, Nagaoka S. Substance P enhances expression of lipopolysaccharide-induced inflammatory factors in dental pulp cells. J Endod 2004; 30(11): 770-774.

9. Gruber R, Jindra C. Proliferation of dental pulp fibroblasts in response to thrombin involves mitogen-activated protein kinase signalling. Int Endod Journal 2004; 37: 145-150.

10. Inoki R, Kudo T, Olgart L. Dynamic aspects of dental pulp. Molecular biology, pharmacology and pathophysiology. Champma and Hall. 1st edition. 1990: 51-69, 385-403.

11. Hargreaves KM, Goodis HE. Seltzer and Bender’s Dental Pulp. Quintessence Books. 2002: 227-281.

12. Slots J, Taubman M. Contemporary Oral Microbiology and Immunology. Mosby Year Book. 1992: 3-24, 533-560.

13. Sugawara S, Arakaki R et al. Lipoteichoic acid acts as an antagonist and an agonist of lipopolysaccharide on human gingival fibroblasts and monocytes in a CD14-Dependent Manner. Infection and Immunity 1999: 1623-1632.

14. Lin S, Yeng-Ping-Kuo M et al. Differential regulation of interleukin-6 and inducible cyclooxygenase gene expression by cytokines trough prostaglandin-depend and-independent mechanisms in human dental pulp fibroblasts. J Endod 2002; 28(3): 197-201.

15. Chao Y, Shun-Fa Y et al. Proinflammatory cytokines induce cyclooxygenase 2 mRNA and protein expression in human pulp cell cultures. J Endod 2003; 29(3): 201-204.

16. Botero T, Shelburne Ch et al. TLR4 mediates LPS-induced VEGF expression in odontoblasts. J Endod 2006; 32(10): 951-955.

17. Su S, Hua K et al. LTA and LPS mediated activation of protein kinases in the regulation of inflammatory cytokines expression in macrophages. Clinica Chimica Acta 2006; 374: 106-115.

18. Lin S, Wang Ch. Induction of dental pulp fibroblast matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 gene expression by interleukin-1a and Tumor Necrosis Factor-a through a prostaglandin-dependent pathway. J Endod 2001; 27(3): 185-189.

19. Kawashima N, Kawanishi H. Effect of NOS inhibitor on cytokine and COX-2 expression in rat pulpitis. J Dent Res 2005; 84(89): 762-767.

20. Jacinto R, Hartung T. Lipopolysaccharide-and Lipoteichoic Acid-induced tolerance and Cross- tolerance: Distinct alterations in IL-1 Receptor-associated kinase. J Immunol 2002; 168: 6136-6141.

21. Chang Y, Lai Ch et al. Stimulation of matrix metalloproteinases by Black-pigmented Bacteroides in human pulp and periodontal ligament cell cultures. J Endod 2002; 28(2): 90-93.

22. Durand S, Flacher V et al. Lipoteichoic acid increases TLR and functional chemokine expression while reducing dentin formation in in vitro differentiated human odontoblasts. J Immuno 2006; 176: 2880-2887.

23. Wu H, Hsieh W et al. Lipoteichoic acid induces prostaglandin E2 release and cyclooxygenase-2 synthesis in rat cortical neuronal cells: Involvement of PKCe and ERK activation. Life Sciences 2006; 79: 272-280.

24. Murray P, Smyth T et al. Analysis of pulpar reactions to restorative procedures, materials, pulp capping, and future therapies. Crit Rev Oral Bio Med 2002; 13(6): 509-520.

25. Chávez PL, Svensater G et al. Streptococci from root canal in tete with apical periodontitis receiving endodontic treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 232-241.

26. 26.Mitsiadis T. Molecular aspects of tooth pathogenesis and repair in vivo an in vitro models. Adv Dent Res 2001; 15: 59-62.

27. Gutierrez G, Maldonado S. Role of p38 in nitric oxide and ciclooxigenase expression, and nitric oxide and PGE2 synthesis in human gingival fibroblasts stimulated with lipopolysaccharides. Life Sciences 2005; 77: 60-73.

28. Willoughby D, Moore A. COX-1, COX-2 and COX3 and the future treatment of chronic inflammatory disease. The Lancet 2000; 335: 646-648.